MGST1 is considered a tumor marker, and its overexpression has been linked to a poor prognosis in several malignancies [48–50], and proposed as a potential therapeutic target for pancreatic cancer [51]. This evidence concerns the gene MGST1 and familial pancreatic carcinoma.